Adverum Stock Analysis

ADVM Stock  USD 0.74  0.06  7.24%   
The recent price roll up of Adverum Biotechnologies could raise concerns from insiders as the firm is trading at a share price of 0.7421 on 33,447 in volume. The company directors and management may have good odds in positioning the firm resources to exploit market volatility in April. The stock standard deviation of daily returns for 90 days investing horizon is currently 3.58. The above-average risk is mostly attributed to market volatility and speculations regarding some of the upcoming earning calls from Adverum Biotechnologies partners.
Check out Trending Equities. To learn how to invest in Adverum Stock please use our How to Invest in Adverum Biotechnologies guide.
The main objective of Adverum Biotechnologies stock analysis is to determine its intrinsic value, which is an estimate of what Adverum Biotechnologies is worth, separate from its market price. There are two main types of Adverum Biotechnologies' stock analysis: fundamental analysis and technical analysis. Fundamental analysis focuses on the financial and economic factors that affect Adverum Biotechnologies' performance, such as revenue growth, earnings, and financial stability. Technical analysis, on the other hand, focuses on the price and volume data of Adverum Biotechnologies' stock to identify patterns and trends that may indicate its future price movements.
The Adverum Biotechnologies stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Adverum Biotechnologies is usually not traded on Thanksgiving Day, Christmas Day, Christmas Day ( substitute day ), New Year 's Monday, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day. Adverum Stock trading window is adjusted to America/New York timezone. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Adverum Biotechnologies' ongoing operational relationships across important fundamental and technical indicators.

Adverum Stock Analysis Notes

About 58.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.3. Some equities with similar Price to Book (P/B) outperform the market in the long run. Adverum Biotechnologies recorded a loss per share of 1.69. The entity had not issued any dividends in recent years. Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California. Adverum Biotechnlgs operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 188 people. For more info on Adverum Biotechnologies please contact Laurent Fischer at 650 656 9323 or go to

Adverum Biotechnologies Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Adverum Biotechnologies' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Adverum Biotechnologies or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Adverum Biotechnologies has some characteristics of a very speculative penny stock
Adverum Biotechnologies appears to be risky and price may revert if volatility continues
Adverum Biotechnologies was previously known as ADVERUM BIOTECHNOLOGIES INC and was traded on NASDAQ Exchange under the symbol AAVL.
The company reported the previous year's revenue of 7.5 M. Net Loss for the year was (145.54 M) with loss before overhead, payroll, taxes, and interest of (81.68 M).
Adverum Biotechnologies currently holds about 235.84 M in cash with (107.83 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.37, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Adverum Biotechnologies has a frail financial position based on the latest SEC disclosures
Roughly 58.0% of the company shares are held by institutions such as insurance companies
Latest headline from Heres Why Were Watching Adverum Biotechnologies Cash Burn Situation

Adverum Biotechnologies Upcoming and Recent Events

Earnings reports are used by Adverum Biotechnologies to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Adverum Biotechnologies previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
4th of April 2023
Upcoming Quarterly Report
11th of May 2023
Next Financial Report
31st of December 2022
Next Fiscal Quarter End
4th of April 2023
Next Fiscal Year End
30th of September 2022
Last Quarter Report
31st of December 2021
Last Financial Announcement

Adverum Biotechnologies SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Adverum Biotechnologies prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Adverum Biotechnologies investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Adverum Biotechnologies specific information freely available to individual and institutional investors to make a timely investment decision.
14th of February 2023
Unclassified Corporate Event
9th of February 2023
Unclassified Corporate Event
8th of February 2023
Unclassified Corporate Event
30th of December 2022
Unclassified Corporate Event
13th of December 2022
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
23rd of November 2022
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
10th of November 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
2nd of September 2022
Unclassified Corporate Event

Adverum Market Capitalization

The company currently falls under 'Micro-Cap' category with a current market capitalization of 78.33 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Adverum Biotechnologies's market, we take the total number of its shares issued and multiply it by Adverum Biotechnologies's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Adverum Profitablity

Adverum Biotechnologies' profitability indicators refer to fundamental financial ratios that showcase Adverum Biotechnologies' ability to generate income relative to its revenue or operating costs. If, let's say, Adverum Biotechnologies is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Adverum Biotechnologies' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Adverum Biotechnologies' profitability requires more research than a typical breakdown of Adverum Biotechnologies' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for 2023
Return on Investment(44.78) (48.32) 
Return on Average Assets(0.35) (0.38) 
Return on Average Equity(0.36) (0.37) 
Return on Invested Capital(0.26) (0.27) 
Return on Sales(17.46) (18.84) 

Management Efficiency

The entity has return on total asset (ROA) of (0.2293) % which means that it has lost $0.2293 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (0.5636) %, meaning that it created substantial loss on money invested by shareholders. Adverum Biotechnologies management efficiency ratios could be used to measure how well adverum biotechnologies manages its routine affairs as well as how well it operates its assets and liabilities. As of 30th of March 2023, Return on Investment is likely to drop to -48.32. In addition to that, Return on Average Assets is likely to drop to -0.38. Adverum Biotechnologies Tangible Asset Value is very stable at the moment as compared to the past year. Adverum Biotechnologies reported last year Tangible Asset Value of 505.69 Million
Last ReportedProjected for 2023
Book Value per Share 3.71  4.51 
Enterprise Value over EBIT(2.30) (2.48) 
Enterprise Value over EBITDA(2.06) (2.23) 
Price to Book Value 0.49  0.51 
Tangible Assets Book Value per Share 5.16  5.76 
Enterprise Value290.5 M377.3 M
Tangible Asset Value505.7 M545.6 M
The analysis of Adverum Biotechnologies' management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Adverum Biotechnologies' future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Adverum Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Non Current Liabilities Total
102.2 M
Interest Expense
Total Operating Expenses
153.6 M
Common Stock Total Equity
10 K

Technical Drivers

As of the 30th of March, Adverum Biotechnologies shows the Downside Deviation of 4.19, risk adjusted performance of 0.1035, and Mean Deviation of 2.92. Adverum Biotechnologies technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to interpolate and analyze data for nineteen technical drivers for Adverum Biotechnologies, which can be compared to its rivals. Please confirm Adverum Biotechnologies variance, value at risk, as well as the relationship between the Value At Risk and skewness to decide if Adverum Biotechnologies is priced correctly, providing market reflects its regular price of 0.7421 per share. As Adverum Biotechnologies is a penny stock we also strongly suggest to validate its total risk alpha numbers.

Adverum Biotechnologies Price Movement Analysis

Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Weighted Moving Average calculates a weight for each value in Adverum Biotechnologies price series with the more recent values given greater weights.

Adverum Biotechnologies Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Adverum Biotechnologies insiders, such as employees or executives, is commonly permitted as long as it does not rely on Adverum Biotechnologies' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Adverum Biotechnologies insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Adverum Biotechnologies Predictive Daily Indicators

Adverum Biotechnologies intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Adverum Biotechnologies stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Adverum Biotechnologies Forecast Models

Adverum Biotechnologies time-series forecasting models is one of many Adverum Biotechnologies' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Adverum Biotechnologies' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Adverum Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Adverum Biotechnologies prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Adverum shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual Stock such as Adverum Biotechnologies. By using and applying Adverum Stock analysis, traders can create a robust methodology for identifying Adverum entry and exit points for their positions.
Last ReportedProjected for 2023
EBITDA Margin(21.60) (23.31) 
Gross Margin 0.90  0.89 
Profit Margin(22.32) (24.08) 

Current Adverum Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Adverum analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Adverum analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
Adverum Biotechnologies current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Adverum analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Adverum stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Adverum Biotechnologies, talking to its executives and customers, or listening to Adverum conference calls.
Adverum Analyst Advice Details

Adverum Stock Analysis Indicators

Adverum Biotechnologies stock analysis indicators help investors evaluate how Adverum Biotechnologies stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Adverum Biotechnologies shares will generate the highest return on investment. By understating and applying Adverum Biotechnologies stock analysis, traders can identify Adverum Biotechnologies position entry and exit signals to maximize returns.
Begin Period Cash Flow63.4 M
Common Stock Shares Outstanding85.1 M
Total Stockholder Equity316.2 M
Total Cashflows From Investing Activities78.7 M
Property Plant And Equipment Net119.1 M
Retained Earnings-648.1 M
Cash And Short Term Investments305.2 M
Retained Earnings Total Equity-648.1 M
Cash34.2 M
Accounts Payable1.4 M
Net Debt-34.2 M
50 Day M A0.7148
Total Current Liabilities21.3 M
Non Current Assets Total122.6 M
Common Stock Total Equity10000.00
Non Currrent Assets Other3.5 M
Stock Based Compensation25.2 M
Check out Trending Equities. To learn how to invest in Adverum Stock please use our How to Invest in Adverum Biotechnologies guide. You can also try ETF Directory module to find actively traded Exchange Traded Funds (ETF) from around the world.

Complementary Tools for analysis

When running Adverum Biotechnologies price analysis, check to measure Adverum Biotechnologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adverum Biotechnologies is operating at the current time. Most of Adverum Biotechnologies' value examination focuses on studying past and present price action to predict the probability of Adverum Biotechnologies' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Adverum Biotechnologies' price. Additionally, you may evaluate how the addition of Adverum Biotechnologies to your portfolios can decrease your overall portfolio volatility.
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Is Adverum Biotechnologies' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adverum Biotechnologies. If investors know Adverum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Adverum Biotechnologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
Quarterly Revenue Growth
Return On Assets
Return On Equity
The market value of Adverum Biotechnologies is measured differently than its book value, which is the value of Adverum that is recorded on the company's balance sheet. Investors also form their own opinion of Adverum Biotechnologies' value that differs from its market value or its book value, called intrinsic value, which is Adverum Biotechnologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Adverum Biotechnologies' market value can be influenced by many factors that don't directly affect Adverum Biotechnologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Adverum Biotechnologies' value and its price as these two are different measures arrived at by different means. Investors typically determine Adverum Biotechnologies value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Adverum Biotechnologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.